Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1995-5-31
pubmed:abstractText
The study of central nervous system (CNS) leukemia has been hampered by the lack of a suitable animal model. We report that severe combined immunodeficiency (SCID) mice invariably develop rapidly progressive fatal CNS leukemia within 3 weeks after intravenous injection of NALM-6 pre-B acute lymphoblastic leukemia (ALL) cells. Colonization of the dura mater and subarachnoid space, usually of the distal spinal cord with occasional extension into the Virchow-Robin spaces of blood vessels subjacent to the meninges, followed involvement of bone marrow in the skull, vertebrae, and, occasionally, the appendicular skeleton. Occult CNS leukemia was detectable by polymerase chain reaction amplification of human DNA as early as 8 days postinoculation of leukemia cells. We used this in vivo model of human CNS leukemia to examine the therapeutic efficacy and toxicity of intrathecally administered B43 (anti-CD19)-pokeweed antiviral protein (PAP), an anti-B-lineage ALL immunotoxin directed against the pan-B-cell antigen CD19/Bp95. Intrathecal therapy with B43 (anti-CD19)-PAP immunotoxin at nontoxic dose levels significantly improved survival of SCID mice and was superior to intrathecal methotrexate therapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2537-45
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:7537120-Animals, pubmed-meshheading:7537120-Antibodies, Monoclonal, pubmed-meshheading:7537120-Antigens, CD, pubmed-meshheading:7537120-Antigens, CD19, pubmed-meshheading:7537120-Antigens, Differentiation, B-Lymphocyte, pubmed-meshheading:7537120-Blood-Brain Barrier, pubmed-meshheading:7537120-Bone Marrow, pubmed-meshheading:7537120-Cell Movement, pubmed-meshheading:7537120-Central Nervous System, pubmed-meshheading:7537120-DNA, Neoplasm, pubmed-meshheading:7537120-Drug Evaluation, Preclinical, pubmed-meshheading:7537120-Immunotoxins, pubmed-meshheading:7537120-Injections, Intraperitoneal, pubmed-meshheading:7537120-Injections, Intravenous, pubmed-meshheading:7537120-Injections, Spinal, pubmed-meshheading:7537120-Leukemic Infiltration, pubmed-meshheading:7537120-Meninges, pubmed-meshheading:7537120-Methotrexate, pubmed-meshheading:7537120-Mice, pubmed-meshheading:7537120-Mice, SCID, pubmed-meshheading:7537120-N-Glycosyl Hydrolases, pubmed-meshheading:7537120-Neoplasm Transplantation, pubmed-meshheading:7537120-Neoplastic Cells, Circulating, pubmed-meshheading:7537120-Plant Proteins, pubmed-meshheading:7537120-Polymerase Chain Reaction, pubmed-meshheading:7537120-Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:7537120-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:7537120-Ribosome Inactivating Proteins, Type 1, pubmed-meshheading:7537120-Specific Pathogen-Free Organisms, pubmed-meshheading:7537120-Transplantation, Heterologous
pubmed:year
1995
pubmed:articleTitle
Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
pubmed:affiliation
Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't